Pharmaceuticals Companies By Cash Per Share
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Cash Per Share
| Cash Per Share | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | TAK | Takeda Pharmaceutical Co | 0.20 | 1.09 | 0.22 | ||
| 2 | RDY | Dr Reddys Laboratories | 0.12 | 1.35 | 0.16 | ||
| 3 | KALA | Kala Pharmaceuticals | 0.07 | 6.05 | 0.42 | ||
| 4 | ARVN | Arvinas | 0.03 | 3.41 | 0.10 | ||
| 5 | NVO | Novo Nordisk AS | (0.05) | 2.49 | (0.13) | ||
| 6 | JAZZ | Jazz Pharmaceuticals PLC | 0.02 | 1.63 | 0.03 | ||
| 7 | JNJ | Johnson Johnson | 0.16 | 1.07 | 0.17 | ||
| 8 | PULM | Pulmatrix | 0.07 | 3.67 | 0.26 | ||
| 9 | TARS | Tarsus Pharmaceuticals | 0.12 | 4.45 | 0.51 | ||
| 10 | HOTH | Hoth Therapeutics | 0.05 | 11.74 | 0.60 | ||
| 11 | NVS | Novartis AG ADR | 0.13 | 1.05 | 0.13 | ||
| 12 | AVIR | Atea Pharmaceuticals | 0.04 | 3.23 | 0.13 | ||
| 13 | ARTL | Artelo Biosciences | (0.05) | 3.86 | (0.18) | ||
| 14 | RLMD | Relmada Therapeutics | 0.07 | 7.10 | 0.50 | ||
| 15 | PCRX | Pacira BioSciences, | (0.10) | 7.22 | (0.73) | ||
| 16 | SUPN | Supernus Pharmaceuticals | 0.12 | 2.49 | 0.29 | ||
| 17 | ITCI | Intracellular Th | 0.03 | 1.82 | 0.06 | ||
| 18 | PFE | Pfizer Inc | 0.07 | 1.29 | 0.09 | ||
| 19 | COCP | Cocrystal Pharma | (0.10) | 4.56 | (0.44) | ||
| 20 | BMY | Bristol Myers Squibb | 0.14 | 2.12 | 0.29 |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it. Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.